المؤلفون: Wang B; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China., Qi FZ; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China., Chen P; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China., Qian LM; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China., Su HS; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China., Wang Y; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China., Wang CH; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China., Hou YX; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China., Zhang Q; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China., Li D; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China., Chen ZS; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, NY, 11439, USA., Zhang SH; Department of Cell Biology, School of Medicine, Nankai University, Tianjin, 300071, China.

المصدر: International journal of biological sciences [Int J Biol Sci] 2024 Feb 11; Vol. 20 (5), pp. 1634-1651. Date of Electronic Publication: 2024 Feb 11 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Ivyspring International Country of Publication: Australia NLM ID: 101235568 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-2288 (Electronic) Linking ISSN: 14492288 NLM ISO Abbreviation: Int J Biol Sci Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Prodrugs*/therapeutic use , Prodrugs*/pharmacology , Nitroimidazoles* , Phosphoramide Mustards*, Humans ; Animals ; Mice ; Cell Hypoxia/physiology ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Hypoxia

المؤلفون: Kishimoto S; Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Brender JR; Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Chandramouli GVR; GenEpria Consulting, Inc., Columbia, Maryland, USA., Saida Y; Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Yamamoto K; Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Mitchell JB; Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Krishna MC; Radiation Biology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

المصدر: Antioxidants & redox signaling [Antioxid Redox Signal] 2021 Oct 10; Vol. 35 (11), pp. 904-915. Date of Electronic Publication: 2020 Sep 15.

نوع المنشور: Journal Article; Research Support, N.I.H., Intramural

بيانات الدورية: Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 100888899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-7716 (Electronic) Linking ISSN: 15230864 NLM ISO Abbreviation: Antioxid Redox Signal Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Carcinoma, Pancreatic Ductal/*therapy , Cell Hypoxia/*drug effects , Nitroimidazoles/*pharmacology , Pancreatic Neoplasms/*therapy , Phosphoramide Mustards/*pharmacology , Prodrugs/*pharmacology, Animals ; Antineoplastic Agents/chemistry ; Carcinoma, Pancreatic Ductal/metabolism ; Carcinoma, Pancreatic Ductal/pathology ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Drug Screening Assays, Antitumor ; Humans ; Mice ; Neoplasms, Experimental/metabolism ; Neoplasms, Experimental/pathology ; Neoplasms, Experimental/therapy ; Nitroimidazoles/chemistry ; Oxidation-Reduction ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/pathology ; Phosphoramide Mustards/chemistry ; Prodrugs/chemistry

المؤلفون: Hegde A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jayaprakash P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Couillault CA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Piha-Paul S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karp D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dumbrava EE; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bhosale P; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Coarfa C; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas., Higgins JP; Molecular Templates, Inc., Austin, Texas., Williams ET; Molecular Templates, Inc., Austin, Texas., Wilson TF; Molecular Templates, Inc., Austin, Texas., Lim J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sumner E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zain H; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nguyen D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Nguyen LM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rajapakshe K; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas., Curran MA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. dshong@mdanderson.org.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jun 01; Vol. 27 (11), pp. 3050-3060. Date of Electronic Publication: 2021 Mar 26.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Head and Neck Neoplasms/*drug therapy , Ipilimumab/*administration & dosage , Melanoma/*drug therapy , Nitroimidazoles/*administration & dosage , Pancreatic Neoplasms/*drug therapy , Phosphoramide Mustards/*administration & dosage , Prostatic Neoplasms/*drug therapy , Squamous Cell Carcinoma of Head and Neck/*drug therapy, Aged ; Female ; Humans ; Ipilimumab/adverse effects ; Male ; Maximum Tolerated Dose ; Middle Aged ; Nitroimidazoles/adverse effects ; Phosphoramide Mustards/adverse effects ; Safety ; Treatment Outcome

المؤلفون: Ding Y; Medical School of Southeast University, Nanjing, 210009, China., Yang R; Research Institute for Reproductive Health and Genetic Diseases, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, 214002, China., Yu W; Medical School of Southeast University, Nanjing, 210009, China., Hu C; Department of Tuberculosis, The Second Affiliated Hospital of Southeast University (The Second Hospital of Nanjing), Nanjing, 210009, China., Zhang Z; Department of Neurosurgery, Nanjing Jinling Hospital, Nanjing University, Nanjing, 210002, China., Liu D; Medical School of Southeast University, Nanjing, 210009, China., An Y; Affiliated Zhongda Hospital of Southeast University, Nanjing, 210009, China., Wang X; Medical School of Southeast University, Nanjing, 210009, China., He C; Medical School of Southeast University, Nanjing, 210009, China., Liu P; Medical School of Southeast University, Nanjing, 210009, China., Tang Q; Medical School of Southeast University, Nanjing, 210009, China. panyixi-tqs@163.com., Chen D; Research Institute for Reproductive Health and Genetic Diseases, The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi, 214002, China. chendaozhen@163.com.

المصدر: Journal of nanobiotechnology [J Nanobiotechnology] 2021 May 19; Vol. 19 (1), pp. 147. Date of Electronic Publication: 2021 May 19.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101152208 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-3155 (Electronic) Linking ISSN: 14773155 NLM ISO Abbreviation: J Nanobiotechnology Subsets: MEDLINE

مواضيع طبية MeSH: Chitosan/*pharmacology , Liposomes/*chemistry , Nitroimidazoles/*pharmacology , Oligosaccharides/*pharmacology , Phosphoramide Mustards/*pharmacology , Photochemotherapy/*methods , Triple Negative Breast Neoplasms/*drug therapy, Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Chitosan/chemistry ; Female ; Humans ; Hyaluronan Receptors ; Hyaluronic Acid ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Nanomedicine ; Nitroimidazoles/chemistry ; Oligosaccharides/chemistry ; Optical Imaging ; Phosphoramide Mustards/chemistry ; Photosensitizing Agents/chemistry ; Prodrugs/chemistry ; Triple Negative Breast Neoplasms/pathology

المؤلفون: Yoon J; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Kang SY; Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea., Lee KH; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Cheon GJ; Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Oh DY; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

المصدر: Cancer research and treatment [Cancer Res Treat] 2021 Apr; Vol. 53 (2), pp. 471-479. Date of Electronic Publication: 2020 Oct 22.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-9256 (Electronic) Linking ISSN: 15982998 NLM ISO Abbreviation: Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Biliary Tract Neoplasms/*drug therapy , Cell Hypoxia/*drug effects , Misonidazole/*analogs & derivatives , Nitroimidazoles/*therapeutic use , Phosphoramide Mustards/*therapeutic use , Positron-Emission Tomography/*methods, Biliary Tract Neoplasms/pathology ; Female ; Humans ; Male ; Middle Aged ; Misonidazole/pharmacology ; Misonidazole/therapeutic use ; Nitroimidazoles/pharmacology ; Phosphoramide Mustards/pharmacology ; Prospective Studies

المؤلفون: Gerard Y; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Voissière A; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Peyrode C; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Galmier MJ; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Maubert E; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Ghedira D; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Tarrit S; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Gaumet V; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Canitrot D; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Miot-Noirault E; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Chezal JM; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France., Weber V; Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont-Ferrand, France. Electronic address: valerie.weber@uca.fr.

المصدر: Bioorganic chemistry [Bioorg Chem] 2020 May; Vol. 98, pp. 103747. Date of Electronic Publication: 2020 Mar 13.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 1303703 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2120 (Electronic) Linking ISSN: 00452068 NLM ISO Abbreviation: Bioorg Chem Subsets: MEDLINE

مواضيع طبية MeSH: Drug Design*, Antineoplastic Agents/*pharmacology , Bone Neoplasms/*drug therapy , Chondrosarcoma/*drug therapy , Neoplasms, Connective and Soft Tissue/*drug therapy , Phosphoramide Mustards/*pharmacology , Prodrugs/*pharmacology, Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Bone Neoplasms/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Chondrosarcoma/pathology ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Molecular Structure ; Neoplasms, Connective and Soft Tissue/pathology ; Phosphoramide Mustards/chemical synthesis ; Phosphoramide Mustards/chemistry ; Prodrugs/chemical synthesis ; Prodrugs/chemistry ; Structure-Activity Relationship

SCR Disease Name: Chondrosarcoma, Extraskeletal Myxoid

المؤلفون: Ma P; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China., Chen J; School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China., Qu H; Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, China., Li Y; Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, China., Li X; Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, China., Tang X; State Key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics, Beijing Institute of Pharmacology and Toxicology, Beijing, China., Song Z; Department of Pathology, The First Medical Center, Chinese PLA General Hospital, Beijing, China., Xin H; Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, China., Zhang J; State Key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics, Beijing Institute of Pharmacology and Toxicology, Beijing, China., Nai J; State Key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics, Beijing Institute of Pharmacology and Toxicology, Beijing, China., Li Z; State Key Laboratory of Toxicology and Medical Countermeasure, Department of Pharmaceutics, Beijing Institute of Pharmacology and Toxicology, Beijing, China., Wang Z; Department of Interventional Radiology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.

المصدر: Drug delivery [Drug Deliv] 2020 Dec; Vol. 27 (1), pp. 1412-1424.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE

مواضيع طبية MeSH: Microspheres*, Antineoplastic Agents/*administration & dosage , Carcinoma, Hepatocellular/*drug therapy , Chemoembolization, Therapeutic/*methods , Liver Neoplasms/*drug therapy , Nitroimidazoles/*administration & dosage , Phosphoramide Mustards/*administration & dosage, Animals ; Antineoplastic Agents/metabolism ; Carcinoma, Hepatocellular/metabolism ; Catheterization ; Cell Hypoxia/drug effects ; Cell Hypoxia/physiology ; Dose-Response Relationship, Drug ; Hep G2 Cells ; Humans ; Liver Neoplasms/metabolism ; Nitroimidazoles/metabolism ; Phosphoramide Mustards/metabolism ; Rabbits

المؤلفون: Jaber MM; Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA., Takahashi T; Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA.; Boston Children's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Kirstein MN; Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA., Al-Kofahi M; Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA., Jacobson PA; Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA., Brundage RC; Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA.

المصدر: Journal of clinical pharmacology [J Clin Pharmacol] 2023 Jan; Vol. 63 (1), pp. 135-142. Date of Electronic Publication: 2022 Sep 29.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*, Humans ; Phosphoramide Mustards/metabolism ; Cyclophosphamide ; Kidney/metabolism

المؤلفون: Delahousse J; Molecular Radiotherapy and Innovative Therapeutics, Unité Mixte de Recherche 1030 INSERM, Gustave Roussy, F-94805, Villejuif, France.; Vectorology and Anticancer Therapies, Unité Mixte de Recherche 8203 Centre National de la Recherche Scientifique, Gustave Roussy, F-94805, Villejuif, France., Skarbek C; Vectorology and Anticancer Therapies, Unité Mixte de Recherche 8203 Centre National de la Recherche Scientifique, Gustave Roussy, F-94805, Villejuif, France., Desbois M; Laboratoire d'immunomonitoring En Oncologie, Gustave Roussy, F-94805, Villejuif, France., Perfettini JL; Molecular Radiotherapy and Innovative Therapeutics, Unité Mixte de Recherche 1030 INSERM, Gustave Roussy, F-94805, Villejuif, France., Chaput N; Laboratoire d'immunomonitoring En Oncologie, Gustave Roussy, F-94805, Villejuif, France.; Laboratory of Genetic Instability and Oncogenesis, Unité Mixte de Recherche 8200 Centre National de la Recherche Scientifique, Gustave Roussy Institute, F-94805, Villejuif, France.; Faculté de Pharmacie, Université Paris-Saclay, F-92296, Chatenay-Malabry, France., Paci A; Molecular Radiotherapy and Innovative Therapeutics, Unité Mixte de Recherche 1030 INSERM, Gustave Roussy, F-94805, Villejuif, France angelo.paci@gustaveroussy.fr.; Faculté de Pharmacie, Université Paris-Saclay, F-92296, Chatenay-Malabry, France.; Pharmacology Department, Gustave Roussy, Villejuif, France.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Aug; Vol. 8 (2).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Cyclophosphamide/*therapeutic use , Immune Checkpoint Inhibitors/*therapeutic use , Phosphoramide Mustards/*therapeutic use, Animals ; Antineoplastic Agents/pharmacology ; Cyclophosphamide/pharmacology ; Disease Models, Animal ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Mice ; Phosphoramide Mustards/pharmacology

المؤلفون: Voelcker G; Institute of Biochemistry II, Goethe University Frankfurt Medical School, Frankfurt, Germany.

المصدر: Anti-cancer drugs [Anticancer Drugs] 2020 Jul; Vol. 31 (6), pp. 617-622.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Alkylating/*toxicity , Cell Proliferation/*drug effects , Cyclophosphamide/*analogs & derivatives , Cyclophosphamide/*toxicity , Leukemia P388/*pathology , Phosphoramide Mustards/*toxicity, Animals ; Antineoplastic Agents, Alkylating/chemistry ; Cyclophosphamide/chemistry ; Female ; Leukemia P388/drug therapy ; Male ; Mice ; Phosphoramide Mustards/chemistry ; Toxicity Tests